|Bid||138.78 x 800|
|Ask||138.80 x 1000|
|Day's Range||137.65 - 139.08|
|52 Week Range||130.96 - 168.11|
|Beta (5Y Monthly)||0.48|
|PE Ratio (TTM)||38.02|
|Earnings Date||Feb 07, 2024 - Feb 12, 2024|
|Forward Dividend & Yield||6.20 (4.49%)|
|Ex-Dividend Date||Jan 12, 2024|
|1y Target Est||169.72|
Subscribe to Yahoo Finance Plus to view Fair Value for ABBV
As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).
AbbVie (NYSE: ABBV) announced today topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type, advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). The results demonstrated a compelling overall response rate per independent central review (ICR) of 35 percent and 23 percent across c-Met High and c-Met Intermediate patients respectively.
AbbVie Inc. ( NYSE:ABBV ) has announced that it will be increasing its dividend from last year's comparable payment on...